Recently, the orthopedic team of the Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine has made new progress in the field of bacterial infection treatment. The researchers prepared a new type of biomaterial-loaded antibiotic that forms a nanoscale drug capsule that can enter the cell, clear the intracellular bacteria like a “bomb”, and destroy the biofilm, enhancing the antibiotic’s ability to kill bacteria inside the biofilm.
The study is expected to provide new methods and new ideas for improving the therapeutic effect of clinical bacterial infection and reducing the recurrence of infection, and the relevant results were recently published online in Advanced Functional Materials.
Schematic diagram of the nanodrug “bomb” targeted elimination of intracellular bacteria Courtesy of the interviewee
Under the guidance of Professor Tang Tingting of Shanghai Jiao Tong University School of Medicine and Zhao Jie, Director of the Department of Orthopedics of the Ninth People’s Hospital, Yang Shengbing, an associate researcher of the Hospital, led the research team to propose a new strategy of using gallium ions to interfere with the metabolism of retaining bacteria to enhance antibiotics to kill retained bacteria, and constructed a new gallium-containing metal-organic framework nanobial material (GaMOF). This nanobiomatrial loaded with antibiotics forms nanoscale drug capsules that can enter the cell to remove intracellular bacteria; At the same time, it can destroy the biofilm and enhance the killing ability of antibiotics to bacteria in the biofilm.
In clinical treatment, the large use of antibiotics is very easy to cause bacteria to develop antibiotic resistance, which is not conducive to the treatment of bacterial infections. The Persister morphology is an important way for bacteria to cope with antibiotic killing, and the holding bacteria can tolerate lethal concentrations of antibiotics when they appear to be temporarily dormant or slow growth inside tissue cells and in biofilms. When the concentration of antibacterial drugs in the patient’s body decreases or the body’s immunity is low, the retaining bacteria will resuscitate from their dormant state, causing a recurrence of infection.
At present, clinically, most of the antibiotics are replaced to combat bacterial resistance mutations, but there is still a lack of effective means to fundamentally solve the antibiotic-tolerant retention bacteria. Therefore, it is particularly urgent to develop a new treatment and clearance strategy for retaining bacteria.
It is reported that the relevant research results have applied for national invention patents, and the clinical transformation application has been steadily advancing. (Source: China Science Daily, Zhang Shuanghu, Huang Xin)
Related paper information:https://doi.org/10.1002/adfm.202204906